Alfuzosin for treatment of lower urinary tract symptoms compatible with benign prostatic hyperplasia: A systematic review of efficacy and adverse effects

Urology

Volumn 66, Issue 4, 2005, Pages 780-788

  MacDonald, Roderick ^a   Wilt, Timothy J ^b  

^a Minneapolis Veterans Affairs Center for Chronic Disease Outcomes Research   (United States)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

ALFUZOSIN; FINASTERIDE;

ADULT; AGED; ARTICLE; ASTHENIA; CLINICAL FEATURE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DISEASE ASSOCIATION; DIZZINESS; DRUG EFFICACY; DRUG FORMULATION; DRUG TOLERABILITY; HEADACHE; HUMAN; IMPOTENCE; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PROSTATE HYPERTROPHY; SIDE EFFECT; TREATMENT OUTCOME; URINARY TRACT DISEASE; URINE FLOW RATE; URINE RETENTION;

ADRENERGIC ALPHA-ANTAGONISTS; HUMANS; MALE; PROSTATIC HYPERPLASIA; QUINAZOLINES; RANDOMIZED CONTROLLED TRIALS; URINATION DISORDERS;

EID: 26644471753     PISSN: 00904295     EISSN: 15279995     Source Type: Journal    
DOI: 10.1016/j.urology.2005.05.001     Document Type: Article

References (26)

1. AUA Practice Guidelines Committee AUA guideline on management of benign prostatic hyperplasia (2003). Chapter 1: Diagnosis and treatment recommendations J Urol 170 2003 530 547
2. M.C. Michel, M.T. Flannery, P. Narayan Worldwide experience with alfuzosin and tamsulosin Urology 58 2001 508 516
3. C.G. Roehrborn Alfuzosin overview of pharmacokinetics, safety, and efficacy of a clinically uroselective alpha-blocker Urology 58 2001 55 63
4. K. McKeage, G.L. Plosker Alfuzosin a review of the therapeutic use of the prolonged-release formulation given once daily in the management of benign prostatic hyperplasia Drugs 62 2002 633 653
5. K. Dickersin, R. Scherer, C. Lefebvre Identifying relevant studies for systematic reviews BMJ 312 1994 944 947
6. K.F. Schultz, I. Chalmers, R.J. Hayes Empirical evidence of bias dimensions of methodological quality associated with estimates of treatment effects in controlled trials JAMA 273 1995 408 412
7. Review Manager [Computer Program], version 4.1, for Windows 2001 The Cochrane Collaboration Oxford, England
8. R. DerSimonian, N. Laird Meta-analysis in clinical trials Control Clin Trials 7 1986 177 188
9. J.M. Buzelin, S. Roth, C. Geffriaud-Ricouard ALGEBI Study Group Efficacy and safety of sustained-release alfuzosin 5 mg in patients with benign prostatic hyperplasia Eur Urol 31 1997 190 198
10. B.E. Carbin, P. Bauer, M. Friskand Efficacy of alfuzosin (an alpha 1-adrenoreceptor blocking drug) in benign hyperplasia of the prostate Scand J Urol Nephrol 138 1991 73 75
11. B.J. Hansen, J. Nordling, H.J. Mensink Alfuzosin in the treatment of benign prostatic hyperplasia: effects on symptom scores, urinary flow rates and residual volume. A multicentre, double-blind, placebo-controlled trial Scand J Urol Nephrol 157 1994 169 176
12. A. Jardin, H. Bensadoun, M.C. Delauche-Cavallier Alfuzosin for treatment of benign prostatic hypertrophy Lancet 337 1991 1457 1461
13. 1-blocker alfuzosin on urodynamic pressure/flow parameters in patients with benign prostatic hyperplasia Eur Urol 32 1997 47 53
14. C.G. Roehrborn Efficacy and safety of once-daily alfuzosin in the treatment of lower urinary tract symptoms and clinical benign prostatic hyperplasia a randomized, placebo-controlled trial Urology 58 2001 953 959
15. C.C. Schulman, W. De Sy, M. Vandendris Belgian multicenter clinical study of alfuzosin, a selective alpha 1-blocker, in the treatment of benign prostatic hyperplasia Acta Urol Belg 62 1994 15 21
16. P. van Kerrebroeck, A. Jardin, K.U. Laval Efficacy and safety of a new prolonged release formulation of alfuzosin 10 mg once daily versus alfuzosin 2.5 mg thrice daily and placebo in patients with symptomatic benign prostatic hyperplasia Eur Urol 37 2000 306 313
17. F.M.J. Debruyne, A. Jardin, D. Colloi Sustained-release alfuzosin, finasteride and the combination of both in the treatment of benign prostatic hyperplasia Eur Urol 34 1998 169 175
18. J.M. Buzelin, E. Fonteyne, M. Kontturi Comparison of tamsulosin with alfuzosin in the treatment of patients with lower urinary tract symptoms suggestive of bladder outlet obstruction (symptomatic benign prostatic hyperplasia) BJU Int 80 1997 597 605
19. 1-adrenoreceptor antagonists, doxazosin and alfuzosin, in patients with lower urinary tract symptoms from benign prostatic enlargement BJU Int 93 2004 757 762
20. C.G. Roehrborn, P. Van Kerrebroeck, J. Nordling Safety and efficacy of alfuzosin 10 mg once-daily in the treatment of lower urinary tract symptoms and clinical benign prostatic hyperplasia a pooled analysis of three double-blind, placebo-controlled studies BJU Int 92 2003 257 261
21. T.J. Wilt, W. Howe, R. MacDonald Terazosin for treating symptomatic benign prostatic obstruction a systematic review of efficacy and adverse effects BJU Int 89 2002 214 225
22. T.J. Wilt, R. MacDonald, D. Nelson Tamsulosin for treating lower urinary tract symptoms compatible with benign prostatic obstruction a systematic review of efficacy and adverse effects J Urol 167 2002 177 183
23. R. MacDonald, T.J. Wilt, R.W. Howe Doxazosin for treating lower urinary tract symptoms compatible with benign prostatic obstruction a systematic review of efficacy and adverse effects BJU Int 94 2004 1263 1270
24. M.J. Barry, W.O. Williford, Y. Chang Benign prostatic hyperplasia specific health status measures in clinical research how much change in the American Urological Association symptom index and the benign prostatic hyperplasia impact index is perceptible to patients? J Urol 154 1995 1770 1774
25. Roehrborn CG, McConnell JD, Barry MJ, et al. AUA Guideline on the Management of Benign Prostatic Hyperplasia. American Urological Association Education and Research, Inc., © 2003. Available at: http://auanet.org/ guidelines/bph.cfm. Accessed January 12, 2005.
26. J.D. McConnell, C. Roehrborn, O.M. Bautista The long-term effect of doxazosin, finasteride, and combination therapy on the clinical progression of benign prostatic hyperplasia N Engl J Med 349 2003 2387 2398